Lenz Therapeutics (NASDAQ: LENZ) raises $80M via block stock sale

Rhea-AI Filing Summary

Lenz Therapeutics, Inc. reported that it sold 1,748,634 shares of common stock on October 7, 2025 at a purchase price of $45.75 per share in a block trade to a single investor. The transaction generated gross proceeds of approximately $80,000,000 for the company. The sale was executed under the company’s existing “at the market” Sales Agreement with TD Securities (USA) LLC, dated April 4, 2025, and was completed pursuant to the terms of that agreement.

Insights

Equity capital markets analyst

Lenz raises $80M through a single-investor block trade under its ATM program.

Lenz Therapeutics completed a sizeable equity sale of 1,748,634 common shares at $45.75 per share for gross proceeds of about $80,000,000. The shares were placed in a single block trade with one investor, using the company’s existing at-the-market Sales Agreement with TD Securities (USA) LLC dated April 4, 2025.

This transaction provides additional cash to the company, while issuing new shares that increase the equity base. Because it was done as a block trade to a single investor under an established ATM agreement, it consolidates the offering into one transaction rather than many smaller open-market sales.

Future filings may clarify how this $80,000,000 capital raise affects the company’s cash position, funding plans, and any subsequent use of the ATM program. Investors can compare later disclosures to understand how frequently the company continues to tap this facility.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

FALSE0001815776Solana BeachCalifornia00018157762025-10-082025-10-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2025

LENZ THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40532

84-4867570

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

201 Lomas Santa Fe Dr., Suite 300
Solana Beach, California						92075
(Address of principal executive offices)						(Zip code)

(858) 925-7000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

LENZ

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 7, 2025, the Company sold 1,748,634 shares of common stock at a purchase price of $45.75 per share for gross proceeds of approximately $80,000,000 in a block trade to a single investor under the Company's "at the market" Sales Agreement with TD Securities (USA) LLC, dated as of April 4, 2025 (the "Sales Agreement"). The sale was made pursuant and subject to the terms of the Sales Agreement, a copy of which was filed with the Current Report on Form 8-K filed by the Company on April 4, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 8, 2025

LENZ THERAPEUTICS, INC.
By:			/s/ Daniel Chevallard
Name:			Daniel Chevallard
Title:			Chief Financial Officer
			(Principal Financial and Accounting Officer)

FAQ

What did Lenz Therapeutics (LENZ) announce in this 8-K filing?

Lenz Therapeutics announced that it sold 1,748,634 shares of its common stock in a block trade to a single investor, generating approximately $80,000,000 in gross proceeds.

At what price did Lenz Therapeutics (LENZ) sell the new shares?

The company sold the shares of common stock at a purchase price of $45.75 per share.

How much capital did Lenz Therapeutics (LENZ) raise in this transaction?

Lenz Therapeutics raised gross proceeds of approximately $80,000,000 from the block trade.

How many shares of Lenz Therapeutics (LENZ) were issued in the block trade?

The company issued 1,748,634 shares of common stock in the transaction.

Under what agreement was the Lenz Therapeutics (LENZ) stock sale conducted?

The sale was conducted under the company’s “at the market” Sales Agreement with TD Securities (USA) LLC, dated April 4, 2025.

Who bought the Lenz Therapeutics (LENZ) shares in this offering?

The filing states that the block trade was made to a single investor, though the investor’s name is not provided in the excerpt.

What type of security did Lenz Therapeutics (LENZ) issue in this transaction?

Lenz Therapeutics issued shares of its common stock, each with a par value of $0.00001 per share.